Clinical Trials
86 trialsUse of Tracking Devices to Locate Abnormalities During Invasive Procedures
National Institutes of Health Clinical Center (CC)
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
National Institutes of Health Clinical Center (CC)
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
University of California, Irvine
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Antelope Surgical Solutions, Inc
PARIS-BIO
Region Stockholm
ARISTA
St. Antonius Hospital Gronau
iCCaRE
University of Ilorin Teaching Hospital
Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses
National Taipei University of Nursing and Health Sciences
Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Lutécio
Instituto do Cancer do Estado de São Paulo
LaserSAFE
University College, London
MOMENT
Prostate Cancer Clinical Trials Consortium
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
University of Southern California
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
DINGO
St Vincent's Hospital, Sydney
TALENT
Prostate Cancer Clinical Trials Consortium
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Acerand Therapeutics Limited
MIDAS-SBRT
University Health Network, Toronto
MIDAS-Prostate
University Health Network, Toronto
ACCESS-PC
Rutgers, The State University of New Jersey
PRO-BOOST-LC
Affidea Nu-med Center of Oncological DIagnostics and Therapy
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Fezo-ADT
Brigham and Women's Hospital
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
The Methodist Hospital Research Institute
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Rezvilutamide for High-Risk Prostate Cancer After Surgery
Fujian Medical University Union Hospital
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Robot-Assisted Radical Prostatectomy: the HOOD Technique Versus Standard Anterior Reconstruction
Ankara University
PSMA PET for Surveillance After Focal Therapy
University of Chicago
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital
DESTINATION 2
The Netherlands Cancer Institute
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
AdventHealth
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer
First Affiliated Hospital of Fujian Medical University
SPAR
Clinique Sainte Clotilde
MicroUSgFLA
University Health Network, Toronto
NICE-PSMA
Martini-Klinik am UKE GmbH
REDI-CaP
National Cancer Institute, Naples
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
M.D. Anderson Cancer Center
CONVERT-HB1
Fudan University
KP-CARAIBES
Centre Hospitalier Universitaire de la Guadeloupe
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
DE-CART
Fox Chase Cancer Center
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Halda Therapeutics OpCo, Inc.
68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
First Affiliated Hospital of Fujian Medical University
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
First Affiliated Hospital of Fujian Medical University
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
Tianjin Medical University Second Hospital
JUMP
Brigham and Women's Hospital